Today’s Research Reports on Stocks to Watch: Axovant Sciences and Johnson & Johnson

NEW YORK, NY / ACCESSWIRE / May 30, 2018 / Biotech company Axovant shares saw a breakout in Tuesday trading after the company announced a new add to its executive team. Shares of Johnson & Johnson were slightly in the red after it was revealed that a jury was hung in South Carolina over whether the company’s baby powder caused a woman cancer. The company also said it would be participating in the Goldman Sachs 39th Annual Global Healthcare Conference next month.

RDI Initiates Coverage on:

Axovant Sciences Ltd.
https://rdinvesting.com/news/?ticker=AXON

Johnson & Johnson
https://rdinvesting.com/news/?ticker=JNJ

Axovant Sciences Ltd. shares broke out in Tuesday trading to see gains of almost 24% on colossal trading volume. The stock traded nearly 6.6 million shares yesterday in comparison to an average of about 723,000 shares. The big gains came after the company announced that Gavin Corcoran, MB BCh, FACP, will join the Company as Executive Vice President of Research & Development, and Michael Hayden, MB ChB, PhD, FRSC, has been appointed as a senior scientific advisor to the company and Chairman of Axovant’s newly established Scientific Advisory Board. CEO Pavan Cheruvu MD, commented, “I am pleased to welcome Gavin and Michael to the Axovant team. Since starting as CEO in February, I have been focused on transforming Axovant into a leaner organization, introducing heightened standards of quality and excellence throughout the business, and establishing a new pipeline strategy. We are now poised for growth, and I am excited to have Gavin and Michael join us as we look toward expanding our pipeline in the coming months.” Dr. Corcoran remarked, “I look forward to working closely with Pavan and the senior management team to bring new investigational medicines into the portfolio as we build upon Axovant’s capabilities in research and development.” The company is a clinical-stage biopharmaceutical company that is dedicated to advancing innovative treatments for patients with serious neurologic and neuropsychiatric conditions.

Access RDI’s Axovant Sciences Ltd. Research Report at:
https://rdinvesting.com/news/?ticker=AXON

Johnson & Johnson shares closed down 1.70% as the market re-opened on Tuesday. The stock traded roughly 9.8 million shares yesterday. It was announced that the company will be participating in the Goldman Sachs 39th Annual Global Healthcare Conference on Tuesday, June 12, at the Terranea Resort in Rancho Palos Verdes, California. At the conference will be Tom Cavanaugh, President, Oncology, Janssen Pharmaceuticals and Scott White, President, Immunology. In other news, it was on Friday that a trial in South Carolina over whether the company’s Baby Powder caused a young woman’s mesothelioma ended in a hung jury. In a similar case in California, a woman had been awarded $25.75 million.

Access RDI’s Johnson & Johnson Research Report at:
https://rdinvesting.com/news/?ticker=JNJ

Our Actionable Research on Axovant Sciences Ltd. (NASDAQ: AXON) and Johnson & Johnson (NYSE: JNJ) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

ReleaseID: 501186